Clonit acquires 100% of Dia.Pro with DLA Piper and Studio Galbiati Sacchi Lamandini e Associati advising

DLA Piper and Studio Galbiati, Sacchi, Lamandini e Associati acted as legal counsel in the transaction: DLA Piper advised Clonit, while Studio Galbiati, Sacchi, Lamandini e Associati represented Dia.Pro and its founding shareholders. Clonit, an Italian company active in the development of molecular tests for infectious and genetic diseases and one of the first firms to develop and certify during the pandemic the CLONIT quanty COVID-19 test bearing the CE‑IVD mark, has acquired 100% of Dia.Pro – Diagnostic Bioprobes from its founding shareholders. The acquisition, executed by Clonit with the support of the private equity vehicle Equita Smart Capital ELTIF managed by Equita Capital SGR, represents a further step in Clonit’s growth strategy aimed at creating a leading group in the diagnostics sector. Spada Partners supported Clonit on the financial and tax due diligence, while Minerva Corporate Finance acted as financial advisor to Clonit in the transaction. DLA Piper represented Clonit with a team composed by: partner Christian Iannaccone; Fulvio Miano (corporate and contractual matters); Giorgia Grande (Golden Power matters). Studio Galbiati, Sacchi, Lamandini e Associati represented Dia.Pro and its founding shareholders with a team composed by: partners Matteo M. Cremascoli and Carla Cannavacciuolo; senior associate Alessandro Calvietti. Spada Partners represented Clonit for financial and tax due diligence with a team composed by: Guido Sazbon, Martina Acciaro, Cristiano Proserpio, Massimo Fagioli, Giorgio Corti. Minerva Corporate Finance acted as financial advisor to Clonit.

Clonit acquires 100% of Dia.Pro with DLA Piper and Studio Galbiati Sacchi Lamandini e Associati advising

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads